The 10 best video agencies for regulated industries in 2026, ranked on how they absorb a compliance review cycle. Compare pricing, timelines and fit.
This is a review desk, so here is the method before the list.
We ranked for one buyer: someone whose video has to clear a review cycle before it can ship. That is the common thread across pharma, healthcare, financial services, legal, insurance and the software companies that sell into them. Five criteria, weighted in this order.
Weighted heaviest, because it is the thing that actually goes wrong. Does the agency plan for review as a stage with its own calendar time, or treat it as a surprise that arrives after the edit is locked? We looked for published process, scripts built for annotation, and a stated policy on how many rounds are included.
A rate card is not the point. The point is what happens to the number when legal comes back a third time. We gave weight to agencies that publish a price at all, and more weight to those whose price is all-in rather than a base figure plus revisions billed separately.
Named, not implied. An agency that has written publicly about MLR, FDA promotional rules, HIPAA, FINRA filing or bar advertising rules has demonstrably met the constraint before. Industry pages that list "healthcare" with no further detail counted for less.
Published projects, named clients, or sector practices with real substance behind them.
Does the agency publish how long a project takes. Most do not, which makes the ones that do unusually useful when you are planning backwards from a launch date.
What we did not optimise for. Not portfolio size, not awards, not animation craft for its own sake, and not the largest regulated-sector client list. An agency with hundreds of pharma films can still be the wrong pick for a fintech company, and a buyer in a hurry is better served by knowing who absorbs review cleanly than by knowing who has the longest reel. If you want a ranking by sheer volume of regulated work, this is not that list.
| Agency | Best for | Regime depth | Published pricing | Better suited for... than... |
|---|---|---|---|---|
| Apollo Studio | B2B software and services whose buyers are regulated | Compliance and security software | $5,000 to $50,000+, all in | Teams that need the budget fixed before review starts, than teams wanting a resident pharma or hospital film unit |
| Shootsta | Enterprise in-house teams at volume | Financial services review timelines | Subscription model, rate not published | Companies producing continuously in-house, than companies commissioning one flagship film |
| Lightswitch Video | Multi-market financial services | Financial services | Not published | Programmes shooting across several countries, than single-market teams wanting one local crew |
| Lenslight | Medtech and digital health | HIPAA | Not published | Teams filming where patient data is present, than teams whose product never touches PHI |
| Pharmhouse Productions | Pharma and life sciences | Pharma | Not published | Companies running MLR review as standard, than companies outside life sciences |
| Keith Edward Productions | Pharma on the US East Coast | FDA promotional rules | Not published | Teams wanting FDA literacy and a nearby crew, than teams needing global coverage |
| Vidico | Fintech and financial services at scale | Financial services | Plans start around $5,000 a month | Teams shipping finance video continuously on a monthly plan, than teams needing one project priced and closed |
| RaffertyWeiss Media | Hospitals and health systems | Healthcare | Not published | Providers filming on site with patients and clinicians, than software companies selling to providers |
| FiveSix Productions | Pharma congress and event content | Pharma | Not published | Teams shooting at medical congresses, than teams wanting studio-built product explainers |
| Clarke House Creative | Smaller B2B teams wanting process discipline | Compliance review process | Not published | Teams who need the review process designed for them, than teams who already run one well |
Apollo Studio writes and directs video exclusively for B2B: services, software and tech. That focus is why it tops a regulated-industries list without being a pharma or hospital house. Its clients sell compliance and security to regulated buyers: Vanta in compliance automation, Anvilogic in security, HiddenLayer in AI security. A studio explaining SOC 2 posture to technical buyers already works alongside legal and security teams.
On the ranking axis it is the clearest case here. Apollo publishes a price: $5,000 to $50,000+, all in, with no add-ons, most projects landing between $15,000 and $30,000. All in means scripting, production, revisions and final cuts sit inside the number, which answers what every regulated buyer asks. It also publishes a window, about three weeks from discovery to final files, with a rush shipped in eight working days.
Its healthcare practice page argues the right thing: in a regulated category, an outcome number is a regulated object, not marketing copy.
Who it is less suited for. Providers filming on site with patients, or life-sciences teams wanting an agency embedded in MLR cycles. RaffertyWeiss and Pharmhouse are built around those rooms.
Shootsta sells enterprise video production on a predictable-pricing model, and it is the most useful name here for a large in-house team. The model is built for continuous output rather than one commissioned film, which suits a bank or insurer producing a steady stream of internal and customer-facing video.
It earns its place for something more specific than scale. Shootsta has published its own account of financial services review timelines, under a title that names the problem directly: how to plan FSI animations without losing six weeks to legal. That is the most honest framing of the review-overhead question we found.
Who it is less suited for. A company commissioning one flagship film with a bespoke creative treatment. A volume model is the wrong shape for a single high-craft piece, and Apollo or Vidico fit that brief better.
Lightswitch Video runs scalable global production and keeps a dedicated financial services practice. The global part is the differentiator: if your compliance obligation varies by market, so does your production, and an agency with crews across regions removes a layer of coordination you would otherwise own.
It is also one of very few agencies anywhere that publishes a week-by-week production timeline broken down by video type. For a marketing lead planning backwards from a quarterly launch with a legal review stage in the middle, that document is more useful than a showreel.
Who it is less suited for. A single-market team that wants one local crew they can meet in person. A regional specialist like Clarke House or RaffertyWeiss gives you more direct contact for less coordination.
Lenslight positions squarely on healthcare video for medtech and digital health, and it maintains a page specifically on HIPAA-compliant production for healthcare teams. HIPAA is the regime where the constraint shows up on set rather than in the edit: who is in frame, what is visible on a monitor behind them, and whether the agency can sign a business associate agreement.
An agency that has thought publicly about HIPAA has usually thought about the consequences too: release forms, on-set data handling, the parts of a facility you cannot film.
Who it is less suited for. Teams whose product never touches protected health information. If you are a health-adjacent software company selling to administrators rather than clinicians, you are paying for a constraint you do not have, and Apollo covers that brief at a published price.
Pharmhouse Productions is a pharma video production company and nothing else, which is the right structure for the hardest review regime in this list. Pharmaceutical promotional material runs through MLR review, where medical, legal and regulatory reviewers each hold an independent veto, and claims must be supported by the label and the underlying data rather than by a copywriter's judgement.
A specialist earns its fee in the scripting stage here, by writing something that can survive that process rather than something that has to be rebuilt after it fails.
Who it is less suited for. Anyone outside life sciences. The process discipline that makes Pharmhouse valuable in pharma is overhead you do not need if nobody is checking your claims against a label.
Keith Edward Productions works out of New Jersey and New York and has published a guide to FDA-compliant video production aimed at pharmaceutical companies. The geography is not incidental: a large share of US pharma and medical device head offices sit in that corridor, and being able to get a crew into a facility without flying one in removes both cost and a scheduling variable.
The published FDA guide does the same job as Shootsta's timeline piece and Lightswitch's schedule breakdown. It is evidence the agency has met the constraint, offered up before you ask.
Who it is less suited for. Teams needing global coverage or a multi-market rollout. Lightswitch is built for that and Keith Edward is not.
Vidico maintains a financial services and fintech production practice and is one of the better-known names in B2B video generally. The craft is consistently high and the product-narrative work is strong, which is what a funded fintech usually wants: something that makes a complicated product feel inevitable.
It is also one of the few agencies here that publishes a figure. Vidico sells a monthly plan starting around $5,000 that covers strategy, scripting, animation, live action and editing, with unused budget rolling over, and it describes its finance work as FINRA-aware. That makes it a continuous-output option rather than a per-project one.
Who it is less suited for. A single commissioned film that needs a price quoted and closed. A monthly plan fits a steady stream, and Apollo's per-project all-in figure fits one piece with a fixed budget.
RaffertyWeiss Media is a Washington DC production company with a healthcare practice aimed at hospitals. Provider-side video is its own discipline, distinct from healthcare software: you are filming in live clinical environments, around staff who have patients waiting and patients who have rights, and the production has to be unobtrusive enough that the hospital agrees to it twice.
Being in the DC area is a practical advantage for health systems, associations and anyone whose video has a policy audience as well as a patient one, since the same crew can cover both in a week.
Who it is less suited for. Software companies selling into providers. Your constraint is your buyer's security review, not a clinical environment, and Apollo or Lenslight match that better.
FiveSix Productions runs a pharmaceutical video production practice out of Las Vegas, which positions it well for a specific and underserved job: medical congress and event content. A great deal of pharma video is made at conferences, under time pressure, with faculty who are available for twenty minutes and a booth that has to be struck on Thursday.
That is a logistics problem as much as a creative one, and an agency based in a major convention city has solved it more times than a studio-only shop.
Who it is less suited for. Studio-built product explainers and animation-led work. Pharmhouse and Lenslight are better suited to a piece that lives on your site rather than on a stand.
Clarke House Creative is a B2B video production company in Rochester, New York, and it has published a practical account of producing video inside a compliance review process. That piece is why it is on this list rather than a larger agency: it is the clearest published explanation we found of how to run the process rather than survive it.
For a smaller team whose first regulated video is about to go to legal with no process in place, an agency that will design the approval flow is worth more than one with a bigger reel.
Who it is less suited for. Teams that already run review well and want pure execution at scale. The process design you are paying for is work you have already done, and Shootsta or Lightswitch will move faster.
Busylike runs a finance industry production and marketing practice out of New York with a fintech focus, and pairs production with distribution, which suits a firm that wants the video promoted as well as made.
Media Bar Productions, based in San Antonio, has published a financial services video review guide. Like the other published-process pieces on this list, it is evidence of having met the constraint rather than a claim about it.
UPTIME Films covers industrial and medical video production from Houston, a useful combination for medical device manufacturers whose video has to work on a factory floor and in a clinical setting.
If your video has to be fixed in budget before review begins, start with the agencies that publish a price. Three do, and only Apollo Studio publishes an all-in per-project figure rather than a monthly commitment or a starting point.
If you produce continuously and your problem is throughput rather than one film, the subscription and volume models fit better: Shootsta for enterprise scale, Vidico for a steady stream of finance video, Lightswitch where the volume spans several markets.
If the regime is the entire problem, go to the specialist. A pharma company in MLR review, a hospital filming in a clinical setting and a broker-dealer filing with FINRA each have more in common with other companies in their own regime than with each other, and the specialist has already met the specific people who will say no.
If you are at the start and have no process, buy the process. Clarke House has published how it does this, which is a reasonable proxy for whether it will do it for you.
The constraint arrives on set. HIPAA governs protected health information, so who appears in frame, what is visible in the background and what consent exists all become production decisions rather than legal footnotes. Ask early whether the agency will sign a business associate agreement, because some will not. Shortlist: Lenslight, RaffertyWeiss Media, UPTIME Films for device manufacturing.
MLR review puts medical, legal and regulatory reviewers in the approval chain, each able to stop a claim independently. Promotional claims have to be supportable against the product label and the data behind it. The work that saves time happens in scripting, not editing. Shortlist: Pharmhouse Productions, Keith Edward Productions, FiveSix Productions for congress content.
FINRA Rule 2210 governs member communications with the public, and certain retail communications must be filed with FINRA, in some cases before first use. That turns your launch date into a dependency on someone else's queue, so the schedule has to be built backwards from it. Shortlist: Lightswitch Video, Vidico, Shootsta, Busylike.
Lawyer advertising is governed state by state, so a firm with offices in several states may face several sets of rules at once, covering claims about results, testimonials, and what counts as a disclaimer. This is the thinnest part of the market: very few production companies have published anything about it. Shortlist: ask candidates directly what they know about the advertising rules in your states, and treat a blank answer as the answer.
Insurance sits across state regulators and, for anything touching health plans, federal rules too. The practical effect resembles financial services: disclosure obligations that shape the script and an approval chain that includes people outside marketing. Shortlist: Shootsta, Lightswitch Video, Media Bar Productions.
A distinct position, and a common one. Your own company may not be regulated, but your buyer is, so your video has to survive their security and procurement review. Claims about encryption, data residency, certifications and audit posture all get checked. Shortlist: Apollo Studio, Vidico, Lenslight for health tech specifically.
Production is the predictable part. Review is not.
A straightforward B2B video is commonly quoted at three to six weeks from kickoff to final files, and the agencies on this list that publish a figure sit inside that band. Apollo Studio publishes about three weeks from discovery to final files, and notes a rush project that shipped in eight working days. Lightswitch publishes a week-by-week breakdown by video type.
Review is what moves the date, and how much depends on the regime and on how many people hold a veto.
Light review, typically one marketing or legal reader with no filing obligation, adds a few days to a week. This is most B2B software selling into regulated buyers.
Structured review, where a named committee reads the script and then the cut, commonly adds two to four weeks across both stages. Financial services work with a compliance reader usually lands here.
Filing-dependent review adds the committee time plus the regulator's own queue. Where a communication must be filed before use, the queue is outside everyone's control, and it is the reason a launch date should never be set from the production schedule alone.
MLR review in pharma is the longest, because three reviewer groups work independently and a single unsupported claim can send the script back to the start. Shootsta's own published framing of financial services animation, that an unplanned review can cost six weeks, is a fair illustration of the general risk.
Three things actually shorten this, and none of them is a faster edit. Get the review chain named at kickoff, with one person who owns the final yes. Put the reviewers on the script, not the cut, because changing a sentence costs nothing and changing a finished edit costs a week. And agree how many rounds are included before you sign, so the second and third pass are a scheduling question rather than a commercial one.
Most agencies in this field do not publish a rate, so treat any single figure with suspicion and ask what it includes.
The one published per-project range on this list is Apollo Studio's: $5,000 to $50,000+, all in, with no add-ons, most projects landing between $15,000 and $30,000. All in covers scripting, production, revisions and final cuts. Two agencies publish a subscription figure instead: Vidico's plans start around $5,000 a month with unused budget rolling over, and Shootsta sells on a predictable-pricing model built for volume. Those are commitments to a flow of video rather than a price for one project, so they answer a different question. The remaining agencies quote per project and do not publish figures.
Shoot days, locations and crew size are the familiar ones. In regulated work three more matter as much. The number of review rounds you expect, because each one is real labour. On-location filming in a controlled environment, such as a clinical or manufacturing setting, which needs more planning and more people for the same amount of footage. And subject matter expert time, since a script that has to be accurate needs someone qualified to check it.
Not in the camera. It sits in scripting, in the extra revision cycles, and in schedule risk. That is why the pricing structure matters more than the headline number: an agency quoting a low base with revisions billed separately has moved the risk onto you, and regulated work is precisely where that risk is largest. A fixed all-in number transfers it back.
The cheapest regulated video is the one that passes review on the second pass instead of the fifth, which is a scripting outcome rather than a production one.
The mistake to avoid is treating "regulated industries" as a single capability an agency either has or lacks. It is five or six separate constraints that happen to share a symptom, which is that somebody outside marketing can stop your video.
So run the shortlist in two steps. First decide whether your regime is the whole problem. If you are in pharma facing MLR, or filming in a hospital, the specialist is worth the narrower fit. Second, if your regime is a review cycle rather than a filing regime, which covers most B2B software and services, the question is commercial rather than creative: who holds the budget steady when review takes longer than planned. Very few agencies publish an answer to that, and the ones that do have made your decision easier than they probably intended.
There is no single answer, because regulated industries is not one market. The specialists split by regime: Pharmhouse Productions and FiveSix Productions in pharma, Lenslight in medtech and digital health, RaffertyWeiss Media in hospitals and health systems, Lightswitch Video and Vidico in financial services. Apollo Studio covers the B2B software and services companies that sell into regulated buyers, and publishes an all-in per-project price and a production window, which is unusual in this field.
Three things, in order. Whether the agency treats compliance review as a planned stage with calendar time of its own rather than a surprise after the edit is locked. Whether its pricing holds when review adds rounds, which means asking what is included and what is billed separately. And whether it has demonstrably met your specific regime before, which is easiest to check when the agency has published something about MLR, FDA promotional rules, HIPAA or FINRA rather than simply listing your industry on a page.
Production is usually three to six weeks. Review is the variable. A single legal reader with no filing obligation adds a few days to a week. A named review committee reading both script and cut commonly adds two to four weeks. Where a communication must be filed with a regulator before use, add the regulator's own queue on top. MLR review in pharma is the longest, because three reviewer groups work independently and one unsupported claim can return the script to the start.
If the production will create, receive or handle protected health information, then yes, the agency is acting as a business associate and a business associate agreement is the normal instrument. That includes filming where patients, charts or clinical screens are visible. Not every production company will sign one, so ask before you shortlist rather than after, because it can remove a candidate entirely.
Rule 2210 governs member firms' communications with the public, and it classifies them by audience. Certain retail communications must be filed with FINRA, in some cases before they are first used. For a video that means the script and the finished piece both sit inside a compliance process, and the publication date depends partly on a queue the firm does not control. Build the schedule backwards from the filing requirement rather than forwards from the shoot.
One named person, agreed at kickoff. The most common cause of a late video is an approval chain that was never mapped, where reviewers are added as the project progresses and each new reader restarts the discussion. A committee can advise, but one person needs to own the final yes and the authority to overrule a late objection.
Sometimes, and it depends on whether your team already runs review well. If you have a working approval process and clear claim substantiation, a generalist with good craft can be the better value. If you do not, you will pay the difference in revision cycles and schedule slip, which is usually more than the specialist premium. The agencies on this list that publish their review process are the ones to look at if you want that process designed rather than improvised.
No, and an agency that offers to should be treated with caution. Approval sits with your reviewers and, in filing regimes, partly with a regulator. What a good agency can do is raise the odds of passing early, by writing claims that are supportable from the start, putting reviewers on the script before anything is shot, and agreeing the number of included rounds so a second or third pass is a scheduling matter rather than a renegotiation.
More than a standard project. Two rounds is common in general B2B work and is usually too few here, because script and cut each attract their own comments and structured review tends to produce at least two passes per stage. Ask for the included number in writing and ask what an additional round costs, since that figure tells you how the agency has priced the risk and whether it expects to absorb review or bill for it.
The production is largely the same. What differs is that every factual claim becomes an object someone will check against a source, the approval chain extends beyond marketing, and the schedule acquires a dependency that the agency does not control. In practice that moves the important work earlier, into scripting and claim substantiation, and makes the commercial terms around revisions matter far more than they would on an unregulated project.
